Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy.

Abstract

Dendritic cell vaccination has been applied to the treatment of a variety of cancers, including malignant astrocytoma. We have treated 13 patients with malignant astrocytoma using dendritic cell vaccination and have shown that this treatment is safe and is likely to be effective in combination with standard adjuvant therapy. Future studies should prospectively incorporate dendritic cell vaccination together with chemotherapy. Ideally, dendritic cell vaccination should be tested in a prospective fashion, in a coordinated trial involving multiple centres.

• Authors: David G Walker, Richard Laherty, Frank H Tomlinson, Teong Chuah, Chris Schmidt
• Journal: Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (J Clin Neurosci) Vol. 15 Issue 2 Pg. 114-21 (Feb 2008) ISSN: 0967-5868 [Print] Scotland
• PMID: 18083572 (Publication Type: Clinical Trial, Phase I, Journal Article)

Chemical References

• CD8 Antigens
• Cancer Vaccines
• Leukocyte Common Antigens

Topics

• Adult
• Aged
• Astrocytoma (pathology, therapy)
• Brain Neoplasms (pathology, therapy)
• CD8 Antigens (metabolism)
• Cancer Vaccines (immunology, therapeutic use)
• Chemotherapy, Adjuvant (methods)
• Dendritic Cells (immunology)
• Female
• Follow-Up Studies
• Humans
• Immunotherapy, Active (methods)
• Leukocyte Common Antigens (metabolism)
• Magnetic Resonance Imaging
• Male
• Middle Aged
• Retrospective Studies